PharmStar Pharmaceuticals CEO to Appear on The Bill Chippas Show

Date : 06/16/2011 @ 9:15AM
Source : Marketwired
Stock : NO^IBGR (NESI)
Quote : 0.95  0.0 (0.00%) @ 2:08AM
Nexus Energy Services, Inc. share price Chart

PharmStar Pharmaceuticals CEO to Appear on The Bill Chippas Show

Nexus Energy Services, Inc. (USOTC:IBGR)
Historical Stock Chart

5 Years : From Feb 2013 to Feb 2018

Click Here for more Nexus Energy Services, Inc. Charts.

PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, announced today that its Chief Executive Officer, Howard Phykitt, will be interviewed on The Bill Chippas Show on Thursday, June 16, 2011, which airs 6:00 PM Eastern Time. Those interested in PharmStar Pharmaceuticals are encouraged to listen live tonight at 6:20 PM ET by visiting or

This will be the third interview for Mr. Phykitt on Bill's show. Mr. Phykitt will discuss his new patent applications as they apply to the Aquaprin technology, announced earlier this week, among other developments with the company. Callers can talk with Mr. Phykitt by calling 1-772-220-9788 or email questions during the show to

Since 2005, Bill has hosted The Bill Chippas Show in South Florida on AM 1590 and AM 1450. Individual investors, active traders and institutional professionals rely on Bill's timely unbiased analysis, deep rooted market background and experience spanning four decades to make intelligent and common sense investments. Bill's weekly Stock Market Comments appear in Weekly Market Strategies delivered by Princeton Research ( to global investors, and Bill's opinion columns appear in In 1996, Bill founded FuturesCom, which remains one of today's longest running Internet-based, independent publications for investment market research. To learn more about Bill, visit

About PharmStar Pharmaceuticals PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Wilson, NC. For more information, visit

Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact: PharmStar, Inc. 919-794-7000 Email Contact: Investor Contact:

Latest NESI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20180222 16:28:00